Skip to main content
Clinical Trials/NCT02959580
NCT02959580
Unknown
Phase 4

Evaluation of Topical Steroids and Surgical Treatment for Idiopathic Granulomatous Mastitis

Peking Union Medical College Hospital1 site in 1 country100 target enrollmentJanuary 1, 2017

Overview

Phase
Phase 4
Intervention
Hydrocortisone Butyrate
Conditions
Granulomatous Mastitis
Sponsor
Peking Union Medical College Hospital
Enrollment
100
Locations
1
Primary Endpoint
clinical response rate
Last Updated
7 years ago

Overview

Brief Summary

This study evaluates the clinical response rate of topical steroids in the treatment of idiopathic granulomatous mastitis in female adults. Half of the participants will receive topical steroid and the other half will receive local wide surgical excision.

Detailed Description

Idiopathic granulomatous mastitis (IGM) is a rare benign inflammatory breast disease of unknown etiology.It may present with many findings that clinically and radiologically mimic breast cancer. Although IGM as a disease has been known for nearly four decades, the optimal treatment approach has not been established. Surgical intervention in the form of wide surgical excision was the mainstay of treatment before 1980, and is still performed depending on local expertise and preference. Currently,surgical treatment and systemic steroid treatment are frequently employed. With the consideration of side effects of longterm systemic (oral) steroid usage, topical steroid without systemic use were assessed and showed satisfactory curative effect. But the data concerning the use of topical steroid therapy are still very limited.

Registry
clinicaltrials.gov
Start Date
January 1, 2017
End Date
September 2020
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Idiopathic Granulomatous Mastitis

Exclusion Criteria

  • Breast Carcinoma

Arms & Interventions

medical

Hydrocortisone butyrate cream(0.1%) was applied to the breast by the patient twice a day on alternate days until the termination of treatment.

Intervention: Hydrocortisone Butyrate

surgical

lesion extended excision

Intervention: extended excision

Outcomes

Primary Outcomes

clinical response rate

Time Frame: six months

The clinical response is categorized into ''completely healed,'' ''inadequately healed,'' ''stable,'' ''worsened,'' or ''relapsed'' if the lesions had once healed but symptoms returned.

Secondary Outcomes

  • granulomatous mastitis recurrence(two years)

Study Sites (1)

Loading locations...

Similar Trials